John M. Barberich

Scriptgen Pharmaceuticals, Inc. discovers and develops small molecule drugs. It develops antifungal and antibacterial drugs, as well as compounds for treatment of hepatitis. The company is headquartered in Medford, MA

Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA.

OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ.

Nordic Biotech Advisors ApS (NB Capital) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2001 by Florian Schönharting and Dr. Christian Hansen, and is owned by a group of institutional investors.

Osteologix Holdings Plc engaged in the development of innovative pharmaceuticals for the treatment and prevention of bone and joint tissues diseases. The company was founded in October 2004 and was headquartered in Dublin, Ireland.

Blue Note Pharmaceuticals is a privately held biopharmaceutical company with offices in Troy, New York and Amsterdam, The Netherlands. Blue Note's mission is to acquire, advance, develop, partner and commercialize carefully selected undervalued drug development candidates with the potential to more effectively treat or help prevent major medical conditions affecting society. The Company's lead development project is BNP 32,762, a pharmacokinetically unique calcium channel blocker (CCB) being evaluated in late-stage clinical trials for the treatment of hypertension and chronic stable angina. Blue Note is also evaluating various products that would combine BNP 32,762 with other commonly accepted antihypertensive drugs such as ACE inhibitors, Angiotensin Receptor Blockers (ARBs) and diuretics. The Company's cardiovascular-oriented pipeline also includes an early-stage program for the prevention of Deep Vein Thrombosis (DVT) and for the treatment of a number of other important cardiovascular indications.